
BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)
Опубликована: Дек. 18, 2024
Язык: Английский
BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)
Опубликована: Дек. 18, 2024
Язык: Английский
Therapeutic Drug Monitoring, Год журнала: 2025, Номер unknown
Опубликована: Янв. 30, 2025
Nirmatrelvir/ritonavir is licensed for the treatment of mild-to-moderate coronavirus disease (COVID-19) in patients at an increased risk progression to severe disease. However, data on real-world plasma exposure nirmatrelvir/ritonavir remain limited, particularly Chinese patients. This study aimed assess trough concentration (Ctrough) and identify its critical factors hospitalized treated with 300 mg/100 mg twice daily over a 5-day course. A high-performance liquid chromatography-tandem mass spectrometry assay was developed validated measure Ctrough. Correlation analyses were performed variables influencing Among 110 patients, 100% had concentrations above antiviral vitro 90% effective concentration. The median Ctrough nirmatrelvir 4.55 mcg/mL (15.6× concentration), ranging from 0.65 12.44 mcg/mL. Nirmatrelvir normal mild renal impairment cohorts comparable (4.09 ± 1.97 4.57 2.21 mcg/mL) but significantly moderate cohort (6.41 2.31 mcg/mL). Sex, age, obesity not associated exposure. high COVID-19, therapeutic drug monitoring should be routinely recommended, except impairment.
Язык: Английский
Процитировано
0International Journal of Antimicrobial Agents, Год журнала: 2024, Номер 64(2), С. 107199 - 107199
Опубликована: Май 24, 2024
Язык: Английский
Процитировано
2Advanced Drug Delivery Reviews, Год журнала: 2024, Номер 211, С. 115364 - 115364
Опубликована: Июнь 25, 2024
Язык: Английский
Процитировано
1Frontiers in Pharmacology, Год журнала: 2024, Номер 15
Опубликована: Сен. 30, 2024
The global elderly population is on the rise, and infections tend to have a higher mortality rate among older individuals. Aging associated with progressive impairment of multi-organ function, which can impact pharmacokinetics antimicrobials, potentially leading failure anti-infective therapy. With increasing life expectancy, significant growth in demographic, escalating costs healthcare, gaining thorough understanding pharmacokinetic changes holds crucial clinical significance. This review compiles findings from published studies, offering comprehensive overview various antimicrobials both adults elderly. Furthermore, it delves into advancements methods specific population.
Язык: Английский
Процитировано
1Infection and Drug Resistance, Год журнала: 2024, Номер Volume 17, С. 4055 - 4065
Опубликована: Сен. 1, 2024
The population pharmacokinetics of nirmatrelvir/ritonavir (NIR/RIT) has not yet been described for critically ill adult patient.
Язык: Английский
Процитировано
0Expert Review of Clinical Pharmacology, Год журнала: 2024, Номер 17(11), С. 1071 - 1079
Опубликована: Сен. 26, 2024
This study aimed to establish population pharmacokinetics (PPK) models of nirmatrelvir/ritonavir in critically ill Chinese patients with the coronavirus disease 2019 (COVID-19) infection, explore factors affecting (PK) nirmatrelvir/ritonavir.
Язык: Английский
Процитировано
0Research Square (Research Square), Год журнала: 2024, Номер unknown
Опубликована: Ноя. 19, 2024
Язык: Английский
Процитировано
0Drug Design Development and Therapy, Год журнала: 2024, Номер Volume 18, С. 5517 - 5527
Опубликована: Дек. 1, 2024
Nirmatrelvir/ritonavir (N/R) is the first drug to receive emergency authorization for treatment of COVID-19 infection. We aimed develop a population pharmacokinetic (PopPK) model evaluate effects potential covariates and explore dosing regimen.
Язык: Английский
Процитировано
0Therapeutic Drug Monitoring, Год журнала: 2024, Номер unknown
Опубликована: Дек. 3, 2024
Background: Paxlovid is a combination of the antiviral agents nirmatrelvir and ritonavir indicated for oral treatment high-risk, symptomatic patients with coronavirus disease 2019 (COVID-19). As real-world data on plasma concentrations nirmatrelvir/ritonavir (Paxlovid) are limited, aim this study was to investigate trough levels in clinical setting using therapeutic drug monitoring. Methods: A prospective, noninterventional, multicenter, observational conducted which were simultaneously determined by liquid chromatography tandem mass spectrometry COVID-19. The blood samples collected days 1, 3, 5 after first full-dose day (day 0), patient such as sex, height, weight, renal function, liver enzymes, concomitant (co-) medications obtained describe respect potential influencing factors. Results: total 46 from 21 analyzed. geometric mean C min 4997 ng/mL 529.4 ritonavir. covered wide range, highest being observed advanced age renally excreted comedications. Patients older than 65 years had significantly higher risk achieving excessive above 8840 1440 compared younger (odds ratio 11.2, 95% confidence interval 1.04–120.4). Conclusions: treated COVID-19 reference values 2210 360 stated product characteristics. Advanced eliminated comedication identified possible factors that warrant further investigation.
Язык: Английский
Процитировано
0BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)
Опубликована: Дек. 18, 2024
Язык: Английский
Процитировано
0